8 results on '"Favre, Claudio"'
Search Results
2. Cardio-Oncology in Childhood: State of the Art.
- Author
-
Bennati, Elena, Girolami, Francesca, Spaziani, Gaia, Calabri, Giovanni Battista, Favre, Claudio, Parrini, Iris, Lucà, Fabiana, Tamburini, Angela, and Favilli, Silvia
- Abstract
Purpose of Review: Cardio-oncology is an increasingly important field of cardiology that focuses on the detection, monitoring, and treatment of cardiovascular disease (CVD) occurring during and after oncological treatments. The survival rate for childhood cancer patients has dramatically increased thanks to new treatment protocols and cardiovascular (CV) sequelae represent the third most frequent cause of mortality in surviving patients. This study aims to provide a complete and updated review of all the main aspects of cardio-oncology in childhood and to highlight the critical issues. Recent Findings: The problem of CV complications in childhood cancer survivors raises the need to make an early diagnosis of cardiotoxicity by the new imaging and laboratory techniques in order to intervene promptly and to implement pharmacological strategies and lifestyle changes to reduce or even to prevent cardiac injury. Furthermore, a stratification of CV risk, also including new predisposing factors such as the presence of some genetic mutations, is of paramount importance before undertaking oncological treatments. Besides, a systematic and personalized planning of long-term follow-up is fundamental to ensure a transition from pediatric to adult hospital and to avoid missed or late diagnosis of cardiomyopathy. Summary: We reviewed the main risk factors for cardiotoxicity in children, both traditional and emerging ones: the mechanisms of toxicity of both old and new antineoplastic therapies, the techniques for detecting cardiac damage, and the current evidence regarding pharmacological cardioprotection. At the end, we focused our attention on the existing guidelines and strategies about the long-term follow-up of childhood cancer survivors. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
3. ALPS, FAS, and beyond: from inborn errors of immunity to acquired immunodeficiencies.
- Author
-
Consonni, Filippo, Gambineri, Eleonora, and Favre, Claudio
- Subjects
HEREDITY ,LYMPHOPROLIFERATIVE disorders ,T cells ,GENETIC variation ,IMMUNITY ,AUTOIMMUNE diseases - Abstract
Autoimmune lymphoproliferative syndrome (ALPS) is a primary immune regulatory disorder characterized by benign or malignant lymphoproliferation and autoimmunity. Classically, ALPS is due to mutations in FAS and other related genes; however, recent research revealed that other genes could be responsible for similar clinical features. Therefore, ALPS classification and diagnostic criteria have changed over time, and several ALPS-like disorders have been recently identified. Moreover, mutations in FAS often show an incomplete penetrance, and certain genotypes have been associated to a dominant or recessive inheritance pattern. FAS mutations may also be acquired or could become pathogenic when associated to variants in other genes, delineating a possible digenic type of inheritance. Intriguingly, variants in FAS and increased TCR αβ double-negative T cells (DNTs, a hallmark of ALPS) have been identified in multifactorial autoimmune diseases, while FAS itself could play a potential role in carcinogenesis. These findings suggest that alterations of FAS-mediated apoptosis could trespass the universe of inborn errors of immunity and that somatic mutations leading to ALPS could only be the tip of the iceberg of acquired immunodeficiencies. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
4. Post-transplantation lymphoproliferative disorder after haematopoietic stem cell transplantation.
- Author
-
Pegoraro, Francesco and Favre, Claudio
- Subjects
- *
STEM cell transplantation , *LYMPHOPROLIFERATIVE disorders , *CYTOTOXIC T cells , *DIAGNOSIS , *PROGNOSIS - Abstract
Post-transplantation lymphoproliferative disorder (PTLD) is a severe complication of haematopoietic stem cell transplantation (HSCT), occurring in a setting of immune suppression and dysregulation. The disease is in most cases driven by the reactivation of the Epstein-Barr virus (EBV), which induces B cell proliferation through different pathomechanisms. Beyond EBV, many factors, variably dependent on HSCT-related immunosuppression, contribute to the disease development. PTLDs share several features with primary lymphomas, though clinical manifestations may be different, frequently depending on extranodal involvement. According to the WHO classification, histologic examination is required for diagnosis, allowing also to distinguish among PTLD subtypes. However, in cases of severe and abrupt presentation, a diagnosis based on a combination of imaging studies and EBV-load determination is accepted. Therapies include prophylactic and pre-emptive interventions, aimed at eradicating EBV proliferation before symptoms onset, and targeted treatments. Among them, rituximab has emerged as first-line option, possibly combined with a reduction of immunosuppression, while EBV-specific cytotoxic T lymphocytes are effective and safe alternatives. Though prognosis remains poor, survival has markedly improved following the adoption of the aforementioned treatments. The validation of innovative, combined approaches is the future challenge. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
5. Off-label caplacizumab as add-on therapy in a 9-year-old boy with refractory aTTP.
- Author
-
Veltroni, Marinella, Pegoraro, Francesco, Scappini, Barbara, Brugnolo, Francesca, Allegro, Elisa, Ermini, Stefano, Tondo, Annalisa, Fotzi, Ilaria, Bambi, Franco, and Favre, Claudio
- Subjects
THROMBOTIC thrombocytopenic purpura ,LEUKOCYTE count ,REFRACTORY materials - Abstract
Despite limited evidence being available on caplacizumab efficacy and safety in younger children, its use in refractory aTTP is a valuable option for patients not responding or relapsing early on conventional therapies. The patient later underwent weekly follow-up evaluations, always remaining in good clinical condition and presenting normal platelets and ADAMTS13 activity (Fig. The patient was finally discharged after 52 days in good clinical condition with a platelet count of 376 × 10 SP 3 sp /µl and an ADAMTS13 activity of 69%. [Extracted from the article]
- Published
- 2022
- Full Text
- View/download PDF
6. The dawn of "immune-revolution" in children: early experiences with checkpoint inhibitors in childhood malignancies.
- Author
-
Lucchesi, Maurizio, Sardi, Iacopo, Puppo, Gianfranco, Chella, Antonio, and Favre, Claudio
- Subjects
CHILDHOOD cancer ,CANCER chemotherapy ,CANCER radiotherapy ,IMMUNOSUPPRESSIVE agents ,CANCER patients - Abstract
Modern immunotherapy with checkpoint inhibitors has changed clinical practice of adult patients with advanced cancer. Blockade of CTLA-4 and PD-1 pathways have shown survival benefits in different diseases. In children, combination of surgery, radiotherapy and chemotherapy have improved survival rates of solid tumors. However, the outcomes for subsets of patients such as those with high-grade, refractory, or metastatic disease remain extremely poor. Currently, the treatment of these patients is almost exclusively based on standard chemotherapy. The significant proportion of pediatric cancers with high number of mutations and subsequent high expression of neoantigens, together with the potential prognostic role of the immunosuppressive checkpoint molecules (CTLA-4, PD-L1) can represent a promising rationale that support the use of checkpoint inhibitors. We made a revision about emerging data regarding safety and activity of checkpoint inhibitors in children with solid tumors. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
7. Pharmacokinetics of high-dose methotrexate in infants aged less than 12 months treated for aggressive brain tumors.
- Author
-
Lucchesi, Maurizio, Guidi, Milena, Fonte, Carla, Farina, Silvia, Fiorini, Patrizio, Favre, Claudio, Martino, Maurizio, Sardi, Iacopo, and de Martino, Maurizio
- Subjects
PHARMACOKINETICS ,METHOTREXATE ,TUMORS in infants ,BRAIN tumor treatment ,LYMPHOBLASTIC leukemia - Abstract
Purpose: In infants aged less than 12 months, there are few data on pharmacokinetics of high-dose methotrexate (MTX) for brain tumors at the dose of 8 g/m(2). Consolidated knowledges are present only with the dose of 5 g/m(2) in acute lymphoblastic leukemia.Methods: We collected data on 8 infants at the time of their first treatment with high-dose MTX, 8 g/m(2), to evaluate the pharmacokinetic profile. All children had a dose adjustment with a weight-based prescription (1 m(2) = 30 kg).Results: The median age was 4.5 months (range 0-9). The median weight was 5.63 kg (range 3.12-9.0). The median steady-state MTX concentration at the end of 6-hr infusion was 486 µM/L (range 227-790). The median systemic MTX clearance was 4.14 L/h/m(2) (range 1.98-9.35). The median MTX concentration after 24 h from the beginning of infusion was 3.29 µM/L (range 1.14-100.44). Three (37.5 %) patients had a delayed elimination of MTX (delayed early, delayed late, or total delayed: one for each). These altered elimination occurred principally in children weighing less than 4 kg (p: 0.0179). Moreover, a systemic MTX clearance at the end of infusion minor than 3 L/h/m(2) can predict a delayed elimination (p: 0.0179). Patients with altered elimination underwent rescue measures (leucovorin supplement and/or exchange transfusion).Conclusions: Our data suggest that a higher dose of MTX for the treatment of aggressive brain tumors in early infants had an acceptable pharmacokinetic profile. Greater attention must be used in the treatment of children weighing less than 4 kg. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
8. Clinical and experimental pharmacokinetic interaction between 6-mercaptopurine and methotrexate.
- Author
-
Innocenti, Federico, Danesi, Romano, Paolo, Antonello, Loru, Barbara, Favre, Claudio, Nardi, Margherita, Bocci, Guido, Nardini, Denise, Macchia, Pierantonio, Tacca, Mario, Innocenti, F, Danesi, R, Di Paolo, A, Loru, B, Favre, C, Nardi, M, Bocci, G, Nardini, D, Macchia, P, and Del Tacca, M
- Subjects
ANIMAL experimentation ,ANTIMETABOLITES ,ANTINEOPLASTIC agents ,BIOAVAILABILITY ,BIOTRANSFORMATION (Metabolism) ,COMPARATIVE studies ,DRUG interactions ,LYMPHOBLASTIC leukemia ,RESEARCH methodology ,MEDICAL cooperation ,METHOTREXATE ,RATS ,RESEARCH ,TIME ,EVALUATION research - Abstract
Clinical and experimental pharmacokinetic interaction between 6-mercaptopurine (6-MP) and methotrexate (MTX) was investigated in patients as well as in rats and in HL-60 human leukemic cells. Ten children affected by acute lymphoblastic leukemia (ALL) in remission received daily doses of 6-MP given at 25 mg/m2 and i.v. infusion of high-dose MTX at 2 or 5 g/m2 once every other week. When 6-MP was given alone, the mean peak plasma concentration (Cmax) and area under the curve (AUC) of 6-MP were 72.5 ng/ml and 225.3 h ng ml(-1). Concurrent treatment with MTX at 2 or 5 g/m2 resulted in a mean increase of 108% and 121% in the Cmax and of 69% and 93% in the AUC, respectively. In rats treated with an oral dose of 6-MP at 75 mg/m2, MTX given i.p. at 5 g/m2 produced mean increases of 110% and 230% in the Cmax and AUC of 6-MP, respectively. In HL-60 human leukemic cells incubated with 6-MP at 250 ng/ml, the cumulative intracellular concentration of 6-thioguanine and 6-MP nucleotides was not significantly modified by treatment with 20 micrograms/ml of MTX. The present findings indicate that high-dose MTX enhances the bioavailability of 6-MP as evidenced by the observed increases in the plasma Cmax and AUC of 6-MP in humans and animals. [ABSTRACT FROM AUTHOR]
- Published
- 1996
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.